Kumar, Atul
Shoai, Maryam
Palmqvist, Sebastian
Stomrud, Erik
Hardy, John
Mattsson-Carlgren, Niklas
Hansson, Oskar
Funding for this research was provided by:
Vetenskapsrådet (2016-00906)
Knut och Alice Wallenbergs Stiftelse (2017-0383)
Marianne and Marcus Wallenberg Foundation (2015.0125)
Alzheimerfonden, Sweden (AF-939932 and AF-930655, AF-939932 and AF-930655)
Swedish Brain Foundation (FO2019-0326 and FO2019-0029, FO2019-0326 and FO2019-0029)
Parkinson foundation of Sweden (1280/20, 1280/20)
Skåne University Hospital Foundation (2020-O000028, 2020-O000028)
Regionalt Forskningsstöd (2020-0314, 2020-0314)
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Bundy Academy, and the Swedish federal government under the ALF agreement (2018-Projekt0279, 2018-Projekt0279)
Lund University
Article History
Received: 8 April 2021
Accepted: 22 September 2021
First Online: 6 October 2021
Competing interests
: AK, MS, SP, ES, JH and NMC have no disclosures. OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. He has received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau and Roche in the past two years.